ZNF419

Summary

ZNF419 (zinc finger protein 419, HGNC:20648) is a protein-coding gene on chromosome 19q13.43, encoding Zinc finger protein 419 (Q96HQ0). May be involved in transcriptional regulation.

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be active in nucleus.

Source: NCBI Gene 79744 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 99 total
• MANE Select transcript: NM_024691

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20648
Approved symbol	ZNF419
Name	zinc finger protein 419
Location	19q13.43
Locus type	gene with protein product
Status	Approved
Aliases	ZAPHIR
Ensembl gene	ENSG00000105136
Ensembl biotype	protein_coding
OMIM	617410
Entrez	79744

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 16 protein_coding, 2 retained_intron

ENST00000221735, ENST00000347466, ENST00000415379, ENST00000424930, ENST00000426954, ENST00000442920, ENST00000518999, ENST00000519310, ENST00000520540, ENST00000521137, ENST00000521754, ENST00000522346, ENST00000523138, ENST00000523312, ENST00000523439, ENST00000523882, ENST00000935995, ENST00000962341

RefSeq mRNA: 10 — MANE Select: NM_024691 NM_001098491, NM_001098492, NM_001098493, NM_001098494, NM_001098495, NM_001098496, NM_001291743, NM_001291744, NM_001291745, NM_024691

CCDS: CCDS42637, CCDS46211, CCDS54325, CCDS54326, CCDS54327, CCDS54328

Canonical transcript exons

ENST00000221735 — 5 exons

Exon	Start	End
ENSE00000728932	57490147	57490185
ENSE00002119234	57487750	57487983
ENSE00003481114	57491471	57491597
ENSE00003655710	57492113	57492211
ENSE00003902818	57492856	57496098

Expression profiles

Bgee: expression breadth ubiquitous, 276 present calls, max score 94.53.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 7.9928 / max 55.3521, expressed in 1724 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
177778	7.1819	1694
177777	0.8109	513

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
olfactory bulb	UBERON:0002264	94.53	silver quality
type B pancreatic cell	CL:0000169	93.93	gold quality
secondary oocyte	CL:0000655	92.37	gold quality
oocyte	CL:0000023	91.38	gold quality
diaphragm	UBERON:0001103	90.30	gold quality
tibialis anterior	UBERON:0001385	89.02	gold quality
ileal mucosa	UBERON:0000331	86.87	silver quality
pancreatic ductal cell	CL:0002079	86.73	silver quality
epithelial cell of pancreas	CL:0000083	86.19	gold quality
tongue squamous epithelium	UBERON:0006919	85.74	silver quality
cortical plate	UBERON:0005343	85.34	gold quality
hair follicle	UBERON:0002073	85.21	gold quality
adenohypophysis	UBERON:0002196	85.19	gold quality
pituitary gland	UBERON:0000007	84.61	gold quality
cerebellar hemisphere	UBERON:0002245	84.22	gold quality
cerebellar cortex	UBERON:0002129	84.17	gold quality
upper arm skin	UBERON:0004263	84.17	gold quality
germinal epithelium of ovary	UBERON:0001304	83.99	gold quality
right hemisphere of cerebellum	UBERON:0014890	83.63	gold quality
thymus	UBERON:0002370	83.61	gold quality
cerebellum	UBERON:0002037	83.42	gold quality
upper leg skin	UBERON:0004262	83.40	gold quality
cervix squamous epithelium	UBERON:0006922	82.95	silver quality
ganglionic eminence	UBERON:0004023	82.93	gold quality
left lobe of thyroid gland	UBERON:0001120	82.92	gold quality
deltoid	UBERON:0001476	82.65	gold quality
thyroid gland	UBERON:0002046	82.49	gold quality
gastrocnemius	UBERON:0001388	82.15	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.13	gold quality
quadriceps femoris	UBERON:0001377	81.90	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	5.23

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
CDKN2A

Upstream regulators (CollecTRI, top): STAT1

miRNA regulators (miRDB)

29 targeting ZNF419, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-7978	99.86	66.90	856
HSA-MIR-377-5P	99.70	65.28	712
HSA-MIR-6086	99.70	65.38	699
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-3120-3P	99.54	70.28	2669
HSA-MIR-543	99.52	69.03	2595
HSA-MIR-199A-5P	99.51	69.71	1107
HSA-MIR-199B-5P	99.51	69.74	1098
HSA-MIR-548G-3P	99.48	68.67	2159
HSA-MIR-653-5P	99.46	67.35	1300
HSA-MIR-5580-5P	99.38	66.96	1139
HSA-MIR-4652-3P	99.33	70.02	2742
HSA-MIR-520E-5P	99.27	68.90	1513
HSA-MIR-3142	98.88	66.09	529
HSA-MIR-1245B-5P	98.88	66.55	576
HSA-MIR-4463	98.56	66.05	1071
HSA-MIR-4299	98.28	66.96	850
HSA-MIR-4469	97.93	65.81	1319
HSA-MIR-1279	97.83	67.50	1898
HSA-MIR-4724-3P	97.57	67.31	785
HSA-MIR-6836-3P	97.08	64.99	712
HSA-MIR-873-3P	96.84	66.09	786
HSA-MIR-4794	96.47	65.53	1063
HSA-MIR-664A-5P	95.84	64.93	949
HSA-MIR-4694-5P	94.62	65.39	532
HSA-MIR-6879-3P	93.93	64.00	759

Literature-anchored findings (GeneRIF, showing 1)

• previously unreported alternative splicing patterns in the genes ZNF419 and DKKL1 (PMID:27826023)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	zfx	ENSDARG00000074453
danio_rerio		ENSDARG00000098424
mus_musculus	Zfy2	ENSMUSG00000000103
mus_musculus	Zfy1	ENSMUSG00000053211
rattus_norvegicus	Zfy1	ENSRNOG00000053042

Paralogs (38): ZFX (ENSG00000005889), ZBTB11 (ENSG00000066422), ZFAT (ENSG00000066827), ZFY (ENSG00000067646), ZNF586 (ENSG00000083828), IKZF5 (ENSG00000095574), ZNF549 (ENSG00000121406), ZSCAN20 (ENSG00000121903), ZNF304 (ENSG00000131845), PRDM15 (ENSG00000141956), ZNF660 (ENSG00000144792), ZNF711 (ENSG00000147180), ZNF773 (ENSG00000152439), ZNF256 (ENSG00000152454), ZNF837 (ENSG00000152475), ZNF691 (ENSG00000164011), ZNF610 (ENSG00000167554), E4F1 (ENSG00000167967), ZNF562 (ENSG00000171466), ZNF561 (ENSG00000171469), ZNF584 (ENSG00000171574), ZIK1 (ENSG00000171649), ZNF570 (ENSG00000171827), ZSCAN2 (ENSG00000176371), ZNF552 (ENSG00000178935), ZNF154 (ENSG00000179909), ZNF792 (ENSG00000180884), ZNF793 (ENSG00000188227), ZNF548 (ENSG00000188785), ZNF79 (ENSG00000196152), ZNF418 (ENSG00000196724), ZNF772 (ENSG00000197128), ZNF583 (ENSG00000198440), ZNF480 (ENSG00000198464), ZNF551 (ENSG00000204519), ZNF134 (ENSG00000213762), ZNF587B (ENSG00000269343), ZNF8 (ENSG00000278129)

Protein

Protein identifiers

Zinc finger protein 419 — Q96HQ0 (reviewed: Q96HQ0)

All UniProt accessions (9): E5RGL3, E5RH62, E5RHS2, E5RHW2, E5RHZ9, E5RI89, E5RIA3, E5RJT6, Q96HQ0

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (6)

UniProt ID	Names	Canonical?
Q96HQ0-1	1	yes
Q96HQ0-2	2
Q96HQ0-3	3
Q96HQ0-4	4
Q96HQ0-5	5
Q96HQ0-6	6

RefSeq proteins (10): NP_001091961, NP_001091962, NP_001091963, NP_001091964, NP_001091965, NP_001091966, NP_001278672, NP_001278673, NP_001278674, NP_078967* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096, PF01352

UniProt features (22 total): zinc finger region 11, splice variant 4, cross-link 2, sequence variant 2, chain 1, domain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96HQ0-F1	70.42	0.28

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 166, 176

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 52 (showing top): XU_HGF_TARGETS_REPRESSED_BY_AKT1_DN, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4, TSENG_IRS1_TARGETS_DN, WANG_HCP_PROSTATE_CANCER, XU_GH1_EXOGENOUS_TARGETS_DN, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, VERHAAK_GLIOBLASTOMA_CLASSICAL, BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_A, SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A12, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, CEBPZ_TARGET_GENES, LCORL_TARGET_GENES, SALL4_TARGET_GENES, ZNF22_TARGET_GENES, MIR4652_3P

GO Biological Process (4): regulation of transcription by RNA polymerase II (GO:0006357), regulation of DNA-templated transcription (GO:0006355), regulation of macromolecule metabolic process (GO:0060255), regulation of primary metabolic process (GO:0080090)

GO Molecular Function (6): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of metabolic process	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
macromolecule metabolic process	1
primary metabolic process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transition metal ion binding	1
nucleic acid binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

604 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF419	HMSD	A8MTL9	571
ZNF419	Q6RUI8	Q6RUI8	522
ZNF419	OR2A2	Q6IF42	479
ZNF419	FREY1	C9JXX5	419
ZNF419	ANGPTL7	O43827	371
ZNF419	CENPM	Q9NSP4	349
ZNF419	KLHL24	Q6TFL4	347
ZNF419	ZNF608	Q9ULD9	340
ZNF419	RSRP1	Q9BUV0	327
ZNF419	HEATR1	Q9H583	325
ZNF419	ZZZ3	Q8IYH5	317
ZNF419	TUBE1	Q9UJT0	309
ZNF419	TOR3A	Q9H497	305
ZNF419	RESF1	Q9HCM1	302
ZNF419	ALOX12B	O75342	300

IntAct

15 interactions, top by confidence:

A	B	Type	Score
KRTAP10-7	ZNF419	psi-mi:“MI:0915”(physical association)	0.560
ZNF419	KRTAP10-7	psi-mi:“MI:0915”(physical association)	0.560
CYSRT1	ZNF419	psi-mi:“MI:0915”(physical association)	0.560
ZNF419	OPTN	psi-mi:“MI:0915”(physical association)	0.560
ZNF419	TRIM39	psi-mi:“MI:0915”(physical association)	0.400
ECE1	ZNF419	psi-mi:“MI:0915”(physical association)	0.370
ZNF419	IPO8	psi-mi:“MI:0914”(association)	0.350
NOTCH2	ZNF320	psi-mi:“MI:0914”(association)	0.350
FYN	ZNF419	psi-mi:“MI:0915”(physical association)	0.000
ZNF419	CYSRT1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (10): KRTAP10-7 (Two-hybrid), ZNF419 (Affinity Capture-RNA), TRIM39 (Affinity Capture-MS), TRIM39 (Affinity Capture-MS), CYSRT1 (Two-hybrid), ZNF419 (Affinity Capture-MS), TRIM39 (Affinity Capture-MS), ZNF419 (Affinity Capture-MS), ZNF419 (Two-hybrid), ZNF419 (Affinity Capture-MS)

ESM2 similar proteins: A0JNB1, A1YF12, A1YG88, A2T759, A3KN32, B2RUI1, O43296, O75123, P10072, P17020, P17097, P51814, P52736, P52740, Q07230, Q08ER8, Q13398, Q14590, Q32KN0, Q3KQV3, Q3MIS6, Q4V8A8, Q5CZA5, Q5RBQ3, Q5RBX0, Q5RCD9, Q5RCX4, Q6GQR8, Q6NX45, Q6P9A3, Q6PK81, Q7TSH9, Q7TSI0, Q7Z7L9, Q86UD4, Q8BFS8, Q8BLB0, Q8IVP9, Q8IZ26, Q8N9F8

Diamond homologs: A0JPL0, A2VDP4, A3KN32, A6NFI3, A6NM28, A6QLU5, B2RXC5, B4DU55, O43296, O60765, O75290, O75467, P10072, P15622, P17014, P17023, P17030, P17031, P17032, P17098, P21506, P51508, P51523, P52736, P52738, Q02975, Q06730, Q06732, Q14590, Q14929, Q16587, Q29RZ4, Q2TL60, Q3KNS6, Q3KQV3, Q49AA0, Q4R8H9, Q4V8A8, Q4V8E9, Q5FWF6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

99 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	82
Likely benign	6
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

853 predictions. Top by Δscore:

Variant	Effect	Δscore
19:57487981:CAGGT:C	donor_loss	1.0000
19:57487983:GGT:G	donor_loss	1.0000
19:57487984:G:A	donor_loss	1.0000
19:57487984:GT:G	donor_loss	1.0000
19:57487985:T:G	donor_loss	1.0000
19:57492184:G:GT	donor_gain	1.0000
19:57492184:G:T	donor_gain	1.0000
19:57491595:TGGGT:T	donor_loss	0.9900
19:57491596:GG:G	donor_gain	0.9900
19:57491597:GG:G	donor_gain	0.9900
19:57491598:G:GA	donor_loss	0.9900
19:57491598:G:GC	donor_loss	0.9900
19:57491598:G:GG	donor_gain	0.9900
19:57491599:T:TC	donor_loss	0.9900
19:57490186:GTA:G	donor_loss	0.9800
19:57490187:T:A	donor_loss	0.9800
19:57490187:T:G	donor_loss	0.9800
19:57491464:TTAG:T	acceptor_loss	0.9800
19:57491464:TTAGC:T	acceptor_loss	0.9800
19:57491465:TAGC:T	acceptor_loss	0.9800
19:57491466:A:AC	acceptor_loss	0.9800
19:57491466:A:AG	acceptor_gain	0.9800
19:57491467:G:GA	acceptor_gain	0.9800
19:57491467:GCA:G	acceptor_gain	0.9800
19:57487826:C:T	donor_gain	0.9700
19:57487863:C:T	donor_gain	0.9700
19:57487984:G:GG	donor_gain	0.9700
19:57490188:AAGTG:A	donor_loss	0.9700
19:57491466:AGCAG:A	acceptor_gain	0.9700
19:57491467:GCAGG:G	acceptor_gain	0.9700

AlphaMissense

3411 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:57493443:T:C	F296L	0.998
19:57493445:C:A	F296L	0.998
19:57493445:C:G	F296L	0.998
19:57493359:T:C	F268L	0.997
19:57493361:T:A	F268L	0.997
19:57493361:T:G	F268L	0.997
19:57493366:G:C	R270P	0.994
19:57493378:T:C	L274P	0.994
19:57493527:T:C	F324L	0.994
19:57493529:T:A	F324L	0.994
19:57493529:T:G	F324L	0.994
19:57493630:T:C	L358P	0.994
19:57493546:T:C	L330P	0.993
19:57493416:T:C	F287L	0.992
19:57493418:T:A	F287L	0.992
19:57493418:T:G	F287L	0.992
19:57493444:T:C	F296S	0.992
19:57493558:A:C	Q334P	0.992
19:57491495:G:C	A33P	0.991
19:57491556:G:C	R53P	0.990
19:57493462:T:C	L302P	0.990
19:57493472:T:A	H305Q	0.990
19:57493472:T:G	H305Q	0.990
19:57493556:T:A	H333Q	0.990
19:57493556:T:G	H333Q	0.990
19:57493645:G:C	R363P	0.990
19:57493779:T:C	F408L	0.990
19:57493781:T:A	F408L	0.990
19:57493781:T:G	F408L	0.990
19:57493947:T:C	F464L	0.990

dbSNP variants (sampled 300 via entrez): RS1000023151 (19:57488614 G>A,T), RS1000354670 (19:57488782 G>C), RS1000836462 (19:57493464 G>A,C,T), RS1001676393 (19:57486782 G>A), RS1001978732 (19:57486428 T>A), RS1002839966 (19:57496288 A>G), RS1003575126 (19:57487147 C>T), RS1003950524 (19:57487391 T>C), RS1004032695 (19:57487108 T>C), RS1004106419 (19:57486882 T>A), RS1004912009 (19:57491383 A>C), RS1005612062 (19:57494803 A>G), RS1005634987 (19:57494442 G>A), RS1005882913 (19:57490440 T>C), RS1005978368 (19:57495838 G>A)

Disease associations

OMIM: gene MIM:617410 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, increases abundance, increases expression, decreases expression	3
Arsenic	affects methylation, affects cotreatment, increases abundance, increases expression	2
Tobacco Smoke Pollution	increases expression	2
Cadmium Chloride	decreases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
TAK-243	increases sumoylation	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
zinc chromate	increases abundance, increases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	increases expression, increases abundance	1
CGP 52608	affects binding, increases reaction	1
abrine	increases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Temozolomide	increases expression	1
Sunitinib	increases expression	1
Air Pollutants	increases abundance, affects expression	1
Benzo(a)pyrene	decreases methylation	1
Catechin	affects cotreatment, decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	increases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Methyl Methanesulfonate	increases expression	1
Ozone	affects expression, increases abundance	1
Plant Extracts	increases expression, affects cotreatment	1
Smoke	decreases expression	1
Valproic Acid	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer